INTRODUCTION
Hepatitis B virus (HBV) is a main cause of human liver diseases [1] [2] [3] . Dysfunction and diseases of liver cells including cirrhosis and hepatocellular carcinoma are the most frequent clinical presentations of hepatitis B [4, 5] . Recent studies revealed that many patients suffer from long term forms of HBV infection including chronic, asymptomatic, and occult (OBI) hepatitis B infection [6] [7] [8] [9] . It appears that the quality and quantity of immune responses against HBV infection determines the fate of infection [9] . It has been shown that HBV may alter specific immune responses through a process of selec-_____________________________________________ Review Article accepted February 17, 2013 tive advantage, meaning that an efficient and complete response to wild-type HBV may result in eradication from the host whereas a cell infected by HBV, harboring a specific mutation, may escape the host's immune system [10] , hence the term 'escape mutation'. This could lead to a long term infection of cells by the mutant-containing HBV. The HBc gene encodes the hepatitis core antigen (HBcAg) which is the epitope that elicits several immune cell responses including those by T helper cells (which respond to HBcAg amino acids 35 -45 and 49 -69), cytotoxic T lymphocytes , and B cells (HBcAg 76 -87 and 105 -116) [11, 12] . Escape mutations within HBcAg epitopes potentially allow HBV to avoid detection and clearance by the host immune system and may represent a mechanism through which infections may persist in some patients. It is worthy to mention that the D genotype is a unique genotype of HBV present in Iran [13] . Hence, it seems that overall genotype variation is not important in the alteration of immune responses among Iranian patients and that specific mutations within the HBV genome, especially in the HBc gene, can be the main viral factor for attenuating immune responses and allowing infection to persist. Therefore, this review draws on current reports regarding HBc gene mutations of HBV isolated from different clinical presentations of Iranian patients suffering from hepatitis B to find the relationship between reported mutations and the outcome of the infection. In order to more comprehensively report the mutation status in the HBc gene, the authors have included a search of the reported gene sequences from Iran in the NCBI nucleotide Gen Bank.
Mutations in HBcAg from amino acids 18 to 27 (the cytotoxic T lymphocyte response region)
Immune responses by cytotoxic CD8 positive T cells to viral infections are the main arm of immune responses that can lead to the complete eradication of viral infections [14] . Previous studies revealed that the amino acids from 18 to 27 of HBcAg are the main region that is recognized by cytotoxic CD8 positive T cells [15] . Therefore, mutations in this region can lead to attenuated cell cytotoxicity responses and, subsequently, persistent HBV infection can occur [16] . Several researchers from Iran have evaluated the mutations in the epitope from amino acids 18 to 27 of HBcAg including our previous study on asymptomatic HBV infected patients which reported that there were no mutations found in this epitope of HBcAg [11] . However, in our search of the GenBank we found a study which reported three mutations T21S, A26S (Gene ID (GI): 54125538), and A21S (GI: 34452647) in this region in chronic hepatitis B infected patients. In addition, other mutations were reported by other researchers as follow: H21S (GI: 190351525), I27V (GI: 190351480), Q21S (GI: 190351471), G21S (GI: 190351246), N21S (GI: 190351182), Y23F (GI: 190351144), Y24F (GI: 190351144) . In addition to the mentioned mutations, Mohebi et al. added another mutation, V21S (GI: 340748298) within the epitope of HBcAg. However, these mutations were also reported by other researchers, but they included the additional mutations M21S (GI: 289598367), S19L (GI: 289598275), and L27V (GI: 289598154). The frequency of mutations targeting Ser21 suggests that this amino acid plays an important role for CTL immune responses. Interestingly, Sendi et al. also demonstrated that Ser21 was the most variable amino acid and that it was substituted by seven different amino acids [16] . It is worthy to mention that the epitope from amino acids 18 to 27 is antigen-presented by HLA-A2 molecules and, hence, this region of HBcAg would typically be recognized by immune cells of HLA-A2 positive patients. In our studies we evaluated the patients with respect to HLA-A2 but no mutations were found in the HLA-A2 positive patients. Moreover, all of the studies mentioned above, with the exception of Sendi et al., did not evaluate HLA-A2 status in the studied patients. Therefore, we cannot rule out the possibility that the reason for long term infection in those reported studies was not caused by mutations in the antigen presentation genes.
Mutations in HBcAg from amino acids 35 -45 and 49 -69 (the T helper lymphocyte response regions)
T helper cells are the main cells responsible for cytokine production and co-stimulatory molecule expression which assists humoral and cellular immunity against viral infections [17, 18] . Previous studies demonstrated that amino acids from 35 to 45 and 49 to 69 with HBcAg can be presented by type 2 MHC antigen presenting cells to T helper cells [16, 19] . Activated T helper cells can help B lymphocytes to induce isotype switching and affinity maturation [20, 21] . T helpers can also help T cytotoxic cells to eradicate viral infections such as HBV [22, 23] . Therefore, mutations in these regions can lead to defective T helper responses and subsequently to compromised humoral and cellular immunity against HBV. Iranian researchers have reported several mutations in the amino acids from 35 to 45 and 49 to 69 of HBcAg. Our study on asymptomatic HBV infected patients showed that there were four mutations (D64E, I66M, N67T, and S69A) in amino acids from 49 to 69, while no mutations were found in amino acids from 35 to 45 [11] . According to our search of Gen Bank, Amini-Bavil-Olyaee et al. [24] . F38Y and D40E are the most common mutations within the 35 -45 region whereas D64E, S69A, T/I66M, and S/N67T are the most common in the 49 -69 region (see Table 1 ). Based on these results, it can be concluded that these mutations may play key roles in the escape of T helper immune responses by HBV. Previous studies revealed that T helpers induce humoral and cellular immunity against viral infections via expression of co-stimulatory molecules and cytokines [18] . Barboza et al. reported that T helper cells of chronic HBV infected patients were unable to increase the expression of CD40L as the main co-stimulatory molecule for macrophage and B lymphocyte activation [25] . Several studies also demonstrated that cytokine production by T helper cells was decreased in hepatitis B infected patients [8, 9, 26] . Therefore, it may be concluded that HBV can escape recognition by T helper lymphocytes especially when they harbor the F38Y and D40E mutations in the 35 -45 region and D64E, S69A, T/I66M, and S/N67T in the 49 -69 region.
Mutations in HBcAg from amino acids 76 -87 and 105 -116 (the B cell lymphocyte response regions)
Humoral immunity is another arm of immune responses, especially in the protection against viral infection [27, 28] . Anti-HBs are protective antibodies that are produced against HBsAg (HBV vaccination components) [29] . Anti-HBc is produced against amino acids 76 -87 as well as to the 105 -116 region of HBcAg [30] . Furthermore, humoral immunity is considered one of the main immune responses against HBV and therefore mutations within the B cell lymphocyte epitope recognition region of HBcAg can be utilized by HBV to escape from these immune responses [31, 32] . Interestingly, we have shown previously that there were three mutations in the 76 -87 region (Q77E, T80I, N87S) and one mutation in the 105 -116 region (L116I) of asymptomatic HBV infected patients [11] . Like other HBc gene regions, our search of GenBank revealed that Amini-Bavil-Olyaee et al. found five mutations Q79P, Q80I that the mentioned mutations were also found in their HBV chronic patients. In addition, they also reported mutations including N78D (GI: 340748661), N67T (GI: 340748592), D77E (GI: 340748256), and A85V (GI: 340748185) within the 76 -87 region and I109T (GI: 340748675), Y107C (GI: 340748585), and M119T (GI: 340748213) within the amino acids from 105 to 116 of HBcAg. Although, these mutations were also reported by Garmiri et al. they also included mutations such as R87S (GI: 289598402) and E84D (GI: 289598317) in the 76 -87 region and M114T (GI: 289598409) and N109T (GI: 289598212) in the 105 -116 region in their report. The most common mutations in the epitope recognized by B cell lymphocytes, in the region from 76 to 87 were those changing Ile80 (Table 1) . Ise80 was replaced by five different amino acids including Glutamine, Proline, Alanine, Threonine and Valine. D/Q77E, A/I/M85V, M/I/V114T and R/T/Q/G/N87S mutations were also reported but with less frequency than mutations in position Ile80. Therefore, it appears that mutations at Glu77, Val85, Ser87, Thr114 and especially Ile80 were seen repeatedly in the B cell lymphocyte epitope recognition region of the HBc gene in HBV infected Iranian patients and these mutations may be a mechanism employed by the virus to escape antibody recognition.
CONCLUSION
According to the reports mentioned above, it seems that the prevalence of HBc gene mutations is frequent in Iranian HBV infected patients. Escape from immune responses is a plausible reason for the high prevalence of HBc gene mutations among Iranian HBV infected patients. Moreover, the studies mentioned above are in reference to the mutations within the HBc gene of chronic and asymptomatic patients and, therefore, may be linked to long term HBV infectivity such as chronic and asymptomatic forms of hepatitis B infection. Therefore, designing a cohort study on acute HBV infected patients in relation to HBc gene mutations and following the outcomes of infections could help find the mutations responsible for induction of long term hepatitis B infection. Previous studies reported that the HBV genotype can affect the outcome of infection. Interestingly, the D genotype is the unique prevalent HBV genotype in Iran [13] ; hence, the genotype does not appear to affect the outcome of disease in Iran, rather, and it would appear that the mutations reported here can be considered more important for disease progression. In addition, based on the high prevalence of OBI in Iranian blood donors [33] , evaluation of these mutations in the long term forms of hepatitis B infection would be of immense value.
